相关实验视频

Updated: May 5, 2026

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

Published on: May 19, 2015

对阿尔茨海默氏病死后大脑的综合空间多态学研究

Yumiko Toyama¹, Takashi Nirasawa², Maho Morishima³

¹Department of Life and Medical Systems, Doshisha University, Kyotanabe, Japan.

Acta histochemica et cytochemica

|July 11, 2024

概括

阿尔茨海默病的研究揭示了大脑中新的粉样β (Aβ) 蛋白质形式. 整合蛋白质组学和成像识别了关键的蛋白质和脂质变化,促进了对AD病原学的理解.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
病理学病理学病理学

背景情况:

阿尔茨海默病 (AD) 在病理上是由β-粉样蛋白 (Aβ) 斑块积累所定义的.
了解Aβ聚合成纤维素对于阐明AD的病原性至关重要.
之前的工作使用MALDI-MSI在死后AD大脑中确定了各种Aβ蛋白质形式.

研究的目的:

使用更新的协议可视化和描述AD大脑中的Aβ蛋白形状.
通过整合蛋白质组学和成像技术来研究Aβ的神经毒性作用.
在AD病理学中探索脂质失调和空间多组学.

主要方法:

使用了更新的矩阵辅助激光脱/电离式质谱成像 (MALDI-MSI) 协议.
集成液体染色学串联质谱学 (LC-MS/MS) 射门蛋白质学与激光微解剖 (LMD).
在死后的AD和控制大脑组织上进行了空间多奥米克分析,包括脂质成像.

主要成果:

始终可视化已知的Aβ蛋白形状,并确定了新的Aβ1-29和Aβ10-40等蛋白形状.
突出显示了微管相关蛋白 (MAP) 和关键AD相关蛋白 (APP,UCHL1,SNCA,APOE) 的动态变化.
证明了整合蛋白质组学和脂质成像的可行性,揭示了大脑各区域的分子病理.

结论:

这项研究成功地可视化了AD大脑中Aβ蛋白质的更广泛的谱.
综合空间多组学方法揭示了与AD相关的蛋白质和脂质的动态变化.
这种方法为揭示阿尔茨海默病的复杂分子病理学提供了一个强大的平台.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的疾病.氨基βββββββββββββββββββββββββ 脂质成像检查脂质成像检查质谱仪成像成像质谱仪成像成像蛋白质组学蛋白质组学

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...